Oxurion NV (TG40)

Overview

Oxurion NV, initially established as ThromboGenics NV in 1991, is a pioneering biopharmaceutical firm based in Leuven, Belgium, with a global operational reach. In September 2018, the company embraced its current identity, Oxurion NV, signifying a strategic evolution in its mission. Oxurion is dedicated to the development and commercialization of innovative treatments targeting eye diseases, leveraging cutting-edge scientific research to improve patient outcomes. Its activities encompass a collaborative ethos, partnering with entities like Bicycle Therapeutics and Galapagos NV to bolster its development pipeline and expand its therapeutic horizons.

Products and Services

JETREA:

As Oxurion NV’s flagship product, JETREA represents a significant advance in the treatment of vitreomacular adhesion/vitreomacular traction. This injectable treatment, grounded in the company's expertise in ophthalmology, offers patients suffering from these conditions a potentially sight-saving option, mitigating the progression towards severe vision loss.

THR-149:

In the pipeline is THR-149, a promising plasma kallikrein inhibitor currently in Phase II clinical trials. Specially formulated to address diabetic macular edema (DME), THR-149 aims to provide a new therapeutic mechanism targeting the underlying processes that exacerbate this condition, which is a leading cause of blindness among adults.

THR-687:

Also in development for the treatment of diabetic macular edema is THR-687, an integrin antagonist. Currently progressing through Phase II clinical trials, THR-687 is designed to counteract the vascular and inflammatory processes that contribute to DME. By blocking specific pathways associated with the disease’s progression, THR-687 demonstrates Oxurion's commitment to offering diverse and innovative treatment options for DME patients.